胸腺恶性肿瘤化疗的相关定义和策略

por Girard, Nicolas, Lal, Rohit, Wakelee, Heather, Riely, Gregory J., Loehrer, Patrick J.
Publicado 2014

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

por Choudhury, Noura J., Riely, Gregory J., Sabbatini, Paul J., Hellmann, Matthew D.
Publicado 2021

One committee to review it all: A single, multi-disciplinary COVID-19 research committee

por Migliacci, Jocelyn, Rodavitch, Ann, Riely, Gregory, Sabbatini, Paul, Houston, Collette, Hanley, Sara
Publicado 2022

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

por Rekhtman, Natasha, Ang, Daphne C., Riely, Gregory J., Ladanyi, Marc, Moreira, Andre L.
Publicado 2013

Management of thymoma‐associated pure red cell aplasia: A novel use of blood substitute HBOC‐201 in a Jehovah’s Witness

por Rubinstein, Maria M., Goss, Cheryl, Avecilla, Scott T., Dubé, Gregory P., Riely, Gregory J., Mones, Jodi V.
Publicado 2019

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency

por Cunanan, Kristen M., Gonen, Mithat, Shen, Ronglai, Hyman, David M., Riely, Gregory J., Begg, Colin B., Iasonos, Alexia
Publicado 2017

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

por Pao, William, Miller, Vincent A, Politi, Katerina A, Riely, Gregory J, Somwar, Romel, Zakowski, Maureen F, Kris, Mark G, Varmus, Harold
Publicado 2005

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

por Pao, William, Wang, Theresa Y, Riely, Gregory J, Miller, Vincent A, Pan, Qiulu, Ladanyi, Marc, Zakowski, Maureen F, Heelan, Robert T, Kris, Mark G, Varmus, Harold E
Publicado 2005

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data

por Ton, Thanh G.N., Pal, Navdeep, Trinh, Huong, Mahrus, Sami, Bretscher, Michael T., Machado, Robson J.M., Sadetsky, Natalia, Chaudhary, Nayan, Lu, Michael W., Riely, Gregory J.
Publicado 2022

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

por Van Egeren, Debra, Kohli, Khushi, Warner, Jeremy L., Bedard, Philippe L., Riely, Gregory, Lepisto, Eva, Schrag, Deborah, LeNoue-Newton, Michele, Catalano, Paul, Kehl, Kenneth L., Michor, Franziska
Publicado 2022

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

por Arbour, Kathryn C., Naidoo, Jarushka, Steele, Keith E., Ni, Ai, Moreira, Andre L., Rekhtman, Natasha, Robbins, Paul B., Karakunnel, Joyson, Rimner, Andreas, Huang, James, Riely, Gregory J., Hellmann, Matthew D.
Publicado 2017

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

por Garcia Campelo, Maria Rosario, Zhou, Caicun, Ramalingam, Suresh S., Lin, Huamao M., Kim, Tae Min, Riely, Gregory J., Mekhail, Tarek, Nguyen, Danny, Goodman, Erin, Mehta, Minal, Popat, Sanjay, Jänne, Pasi A.
Publicado 2022

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors

por Sato, Hiroki, Kubota, Daisuke, Qiao, Huan, Jungbluth, Achim, Rekhtman, Natasha, Schoenfeld, Adam J., Yu, Helena A., Riely, Gregory J., Toyooka, Shinichi, Lovly, Christine M., Paik, Paul, Ladanyi, Marc, Fan, Pang-Dian
Publicado 2022

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

por Thummalapalli, Rohit, Choudhury, Noura J., Ehrich, Fiona, Beardslee, Tyler, Brazel, Danielle, Zhang, Shannon S., Merchant, Shelby, Chen, Monica F., Heller, Glenn, Ramalingam, Suresh S., Ou, Sai-Hong Ignatius, Mileham, Kathryn F., Riely, Gregory J.
Publicado 2023

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

por Ou, Sai-Hong Ignatius, Socinski, Mark A, Gadgeel, Shirish, Gandhi, Leena, West, Howard, Chiappori, Alberto Alejandro, Cohen, Victor, Riely, Gregory J, Smoljanovic, Vlatka, Bordogna, Walter, Wright, Elaine, Debusk, Kendra, Zeaiter, Ali, Shaw, Alice T
Publicado 2018

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer

por Thummalapalli, Rohit, Bernstein, Ezra, Herzberg, Benjamin, Li, Bob T., Iqbal, Afsheen, Preeshagul, Isabel, Santini, Fernando C., Eng, Juliana, Ladanyi, Marc, Yang, Soo-Ryum, Shen, Ronglai, Lito, Piro, Riely, Gregory J., Sabari, Joshua K., Arbour, Kathryn C.
Publicado 2023

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer

por Suzawa, Ken, Offin, Michael, Schoenfeld, Adam J., Plodkowski, Andrew J., Odintsov, Igor, Lu, Daniel, Lockwood, William W., Arcila, Maria E., Rudin, Charles M., Drilon, Alexander, Yu, Helena A., Riely, Gregory J., Somwar, Romel, Ladanyi, Marc
Publicado 2019

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

por Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius
Publicado 2022

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

por Drilon, Alexander, Rekhtman, Natasha, Arcila, Maria, Wang, Lu, Ni, Andy, Albano, Melanie, Van Voorthuysen, Martine, Somwar, Romel, Smith, Roger S., Montecalvo, Joseph, Plodkowski, Andrew, Ginsberg, Michelle S., Riely, Gregory J., Rudin, Charles M., Ladanyi, Marc, Kris, Mark G.
Publicado 2016

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy

por Jackson, Christopher B., Rimner, Andreas, Simone, Charles B., Lebow, Emily S., Huang, James, Lobaugh, Stephanie M., Zhang, Zhigang, Riely, Gregory J., Ginsberg, Michelle S., Pagano, Andrew M., Chang, Jason C., Mayoral, Maria, Gomez, Daniel G., Shepherd, Annemarie F.
Publicado 2022